Table 1

Baseline characteristics of the study population matched for age and sex

StatinMatched control
MaleFemaleMaleFemale
N175 506177 996526 518533 988
Age (mean±SD)65.02±10.8969.02±10.4665.02±10.8969.02±10.46
Osteoporosis (M80–M82)1765
(1.01%)
9936
(5.58%)
5.264
(1.00%)
26.903
(5.04%)**
Insulin11 690
(6.66%)
12 332
(6.93%)
8603**
(1.63%)
8617**
(1.61%)
Oral antidiabetics34 511
(19.66%)
32 514
(18.27%)
32 569**
(6.19%)
31 237**
(5.85%)
Fibrates3667
(2.09%)
1993
(1.12%)
6470**
(1.23%)
8131**
(1.52%)
Arthritis (M06)359
(0.20%)
991
(0.56%)
988
(0.19%)
2.703*
(0.51%)
CVD (I20–I25)36 970
(21.06%)
23 998
(13.48%)
33 971
(6.45%)
27 814**
(5.21%)
Stroke (I63, I64)5164
(2.94%)
4429
(2.49%)
8250**
(1.57%)
7875**
(1.47%)
Diseases of arteries (I70–I79)12 513
(7.13%)
9058
(5.09%)
17 621**
(3.35%)
13 605**
(2.55%)
Renal failure (N17–N19)8148
(4.64%)
6684
(3.76%)
15 774**
(3.00%)
14 039**
(2.63%)
Overweight and obesity (E66)8314
(4.74%)
8290
(4.66%)
10 913**
(2.07%)
13 526**
(2.53%)
Nicotine dependency (F17)4.215
(2.40%)
1766
(0.99%)
6925**
(1.32%)
2422**
(0.45%)
  • We give group size, age and the absolute and relative frequencies of osteoporosis, use of other medications (insulin, metformin, fibrates) and comorbid conditions for males and females in the statin-treated and control group, respectively.

  • **P<0.01; *p<0.05.

  • CVD, cardiovascular disease.